WASHINGTON - Novo Nordisk reported on Nov. 14 at ObesityWeek 2026 that lower doses of its investigational obesity drug CagriSema achieved roughly 21% average weight loss in the Phase 3 REDEFINE 9 trial. The findings were simultaneously published in The Lancet Diabetes & Endocrinology.
What happened?
The 68-week double-blind trial enrolled 309 adults with overweight or obesity and no diabetes, testing fixed combinations below the previously studied 2.4 mg/2.4 mg ceiling. Under the efficacy estimand, both the 1.7 mg/1.7 mg and 1.0 mg/1.0 mg doses delivered approximately 21% weight loss compared with 2.0% for placebo. Roughly 70% of treated participants lost at least 15% of body weight, and around half achieved 20% or greater reductions.
Why does it matter?
Strong efficacy at reduced doses gives physicians concrete dosing flexibility when managing patient tolerability. "Novo's investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology," the company stated on Nov. 14. Adverse-event discontinuations remained low at 2.9% and 4.9% across active arms, matching placebo's 4.9% rate.
What comes next?
Novo Nordisk submitted a New Drug Application to the FDA in December 2025 for CagriSema 2.4 mg/2.4 mg, with a regulatory decision expected in the fourth quarter of 2026. Because REDEFINE 9 was not powered to compare active doses directly, future label updates will depend on FDA review.
